Form POSASR Mersana Therapeutics,

Go back to Form POSASR Mersana Therapeutics,

BTIG Upgrades Mersana (MRSN) to Buy

February 28, 2024 3:38 PM EST

BTIG analyst Kaveri Pohlman upgraded Mersana (NASDAQ: MRSN) from Neutral to Buy with a price target of $6.00.

The analyst comments "We believe that the upcoming catalysts this year could significantly de-risk the Dolasynthen platform and the lead ADC, XMT-1660 (B7-H4 Dolalock ADC),... More